220 related articles for article (PubMed ID: 28653251)
1. Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer.
Takayoshi K; Kusaba H; Uenomachi M; Mitsugi K; Makiyama C; Makiyama A; Uchino K; Shirakawa T; Shibata Y; Shinohara Y; Inadomi K; Tsuchihashi K; Arita S; Ariyama H; Esaki T; Akashi K; Baba E
Cancer Chemother Pharmacol; 2017 Aug; 80(2):333-342. PubMed ID: 28653251
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study.
Gulhati P; Raghav K; Shroff RT; Varadhachary GR; Kopetz S; Javle M; Qiao W; Wang H; Morris J; Wolff RA; Overman MJ
Cancer; 2017 May; 123(6):1011-1017. PubMed ID: 27859010
[TBL] [Abstract][Full Text] [Related]
3. Addition of Bevacizumab to First-Line Palliative Chemotherapy in Patients with Metastatic Small Bowel Adenocarcinoma: A Population-Based Study.
Legué LM; van Erning FN; Bernards N; Lemmens VEPP; de Hingh IHJT; Creemers GJ
Target Oncol; 2019 Dec; 14(6):699-705. PubMed ID: 31625001
[TBL] [Abstract][Full Text] [Related]
4. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Bevacizumab in Advanced Small Bowel Adenocarcinoma.
Aydin D; Sendur MA; Kefeli U; Ustaalioglu BB; Aydin O; Yildirim E; Isik D; Ozcelik M; Surmeli H; Oyman A; Isik S; Sener N; Ercelep O; Odabas H; Aliustaoglu M; Gumus M
Clin Colorectal Cancer; 2017 Mar; 16(1):78-83. PubMed ID: 27247089
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of the FOLFOX/CAPOX regimen for advanced small bowel adenocarcinoma: a three-center study from China.
Zhang L; Wang LY; Deng YM; Wang FH; Feng F; Chen YC; An X; Chen C; Xu RH; Li YH
J BUON; 2011; 16(4):689-96. PubMed ID: 22331723
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma.
Horimatsu T; Nakayama N; Moriwaki T; Hirashima Y; Fujita M; Asayama M; Moriyama I; Nakashima K; Baba E; Kitamura H; Tamura T; Hosokawa A; Yoshimura K; Muto M
Int J Clin Oncol; 2017 Oct; 22(5):905-912. PubMed ID: 28536826
[TBL] [Abstract][Full Text] [Related]
8. S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.
Hironaka S; Sugimoto N; Yamaguchi K; Moriwaki T; Komatsu Y; Nishina T; Tsuji A; Nakajima TE; Gotoh M; Machida N; Bando H; Esaki T; Emi Y; Sekikawa T; Matsumoto S; Takeuchi M; Boku N; Baba H; Hyodo I
Lancet Oncol; 2016 Jan; 17(1):99-108. PubMed ID: 26640036
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.
Overman MJ; Varadhachary GR; Kopetz S; Adinin R; Lin E; Morris JS; Eng C; Abbruzzese JL; Wolff RA
J Clin Oncol; 2009 Jun; 27(16):2598-603. PubMed ID: 19164203
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer.
Nishina T; Kato T; Yamazaki K; Yoshino T; Miyata Y; Esaki T; Moriwaki T; Boku N; Hyodo I
Cancer Chemother Pharmacol; 2015 Sep; 76(3):547-53. PubMed ID: 26198316
[TBL] [Abstract][Full Text] [Related]
11. North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma.
McWilliams RR; Foster NR; Mahoney MR; Smyrk TC; Murray JA; Ames MM; Horvath LE; Schneider DJ; Hobday TJ; Jatoi A; Meyers JP; Goetz MP
Cancer; 2017 Sep; 123(18):3494-3501. PubMed ID: 28493308
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy in advanced small bowel adenocarcinoma.
Locher C; Malka D; Boige V; Lebray P; Elias D; Lasser P; Ducreux M
Oncology; 2005; 69(4):290-4. PubMed ID: 16282708
[TBL] [Abstract][Full Text] [Related]
13. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
Sogabe S; Komatsu Y; Yuki S; Kusumi T; Hatanaka K; Nakamura M; Kato T; Miyagishima T; Hosokawa A; Iwanaga I; Sakata Y; Asaka M
Jpn J Clin Oncol; 2011 Apr; 41(4):490-7. PubMed ID: 21303790
[TBL] [Abstract][Full Text] [Related]
14. Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal Adenocarcinoma.
Li J; Yao X; Kortmansky JS; Fischbach NA; Stein S; Deng Y; Zhang Y; Doddamane I; Karimeddini D; Hochster HS; Lacy J
Am J Clin Oncol; 2017 Apr; 40(2):146-151. PubMed ID: 25144267
[TBL] [Abstract][Full Text] [Related]
15. Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer.
Komatsu Y; Ishioka C; Shimada K; Yamada Y; Gamoh M; Sato A; Yamaguchi T; Yuki S; Morita S; Takahashi S; Goto R; Kurihara M
BMC Cancer; 2015 Sep; 15():626. PubMed ID: 26353772
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Masi G; Loupakis F; Salvatore L; Fornaro L; Cremolini C; Cupini S; Ciarlo A; Del Monte F; Cortesi E; Amoroso D; Granetto C; Fontanini G; Sensi E; Lupi C; Andreuccetti M; Falcone A
Lancet Oncol; 2010 Sep; 11(9):845-52. PubMed ID: 20702138
[TBL] [Abstract][Full Text] [Related]
17. Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy.
Tsushima T; Taguri M; Honma Y; Takahashi H; Ueda S; Nishina T; Kawai H; Kato S; Suenaga M; Tamura F; Morita S; Boku N
Oncologist; 2012; 17(9):1163-70. PubMed ID: 22622149
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
Hochster HS; Hart LL; Ramanathan RK; Childs BH; Hainsworth JD; Cohn AL; Wong L; Fehrenbacher L; Abubakr Y; Saif MW; Schwartzberg L; Hedrick E
J Clin Oncol; 2008 Jul; 26(21):3523-9. PubMed ID: 18640933
[TBL] [Abstract][Full Text] [Related]
20. S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies.
Iwasa S; Nagashima K; Yamaguchi T; Matsumoto H; Ichikawa Y; Goto A; Yasui H; Kato K; Okita NT; Shimada Y; Yamada Y
Cancer Chemother Pharmacol; 2015 Sep; 76(3):605-14. PubMed ID: 26220845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]